香雪制药(300147) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter was RMB 437.02 million, a decrease of 17.05% year-over-year[2] - Net profit attributable to shareholders was RMB -82.58 million, a decrease of 3.12% year-over-year[2] - Basic earnings per share were RMB -0.12, unchanged from the previous year[2] - Weighted average return on equity was -4.71%, a decrease of 1.22 percentage points year-over-year[3] - Total operating income decreased to 1,533,560,038.60 RMB from 1,728,181,516.45 RMB[16] - Net profit loss increased to -196,889,583.22 RMB from -131,891,114.43 RMB[17] - Basic earnings per share decreased to -0.3300 RMB from -0.2200 RMB[18] - Comprehensive income loss increased to -196,954,831.78 RMB from -134,661,608.51 RMB[18] - Sales revenue from goods and services dropped to 1.35 billion yuan from 1.52 billion yuan[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8.05 billion, a decrease of 2.74% compared to the end of the previous year[3] - Equity attributable to shareholders was RMB 1.71 billion, a decrease of 11.32% compared to the end of the previous year[3] - The company's monetary funds decreased from RMB 149,316,999.85 to RMB 75,596,495.08 compared to the beginning of the period[13] - Accounts receivable increased from RMB 704,939,229.85 to RMB 851,565,743.05 compared to the beginning of the period[13] - Inventory increased from RMB 411,297,654.94 to RMB 420,980,343.45 compared to the beginning of the period[13] - Total assets decreased from RMB 8,280,629,979.39 to RMB 8,054,105,393.38 compared to the beginning of the period[14] - Short-term borrowings decreased from RMB 1,498,076,786.19 to RMB 1,443,123,454.16 compared to the beginning of the period[14] - Accounts payable increased from RMB 1,084,760,267.86 to RMB 1,173,286,369.91 compared to the beginning of the period[14] - Total liabilities decreased from RMB 5,161,681,554.89 to RMB 5,156,548,087.13 compared to the beginning of the period[14] - Total liabilities decreased to 5,937,422,398.18 RMB from 5,967,412,152.41 RMB[15] - Total equity decreased to 2,116,682,995.20 RMB from 2,313,217,826.98 RMB[15] Cash Flow - Operating cash flow for the period was RMB -36.16 million, a decrease of 118.84% year-over-year[2] - Operating cash flow decreased to -36.16 million yuan from 191.97 million yuan in the previous period[19] - Investment cash flow improved to 27.95 million yuan from -40.69 million yuan[20] - Financing cash flow was -61.28 million yuan compared to -195.22 million yuan in the previous period[20] - Net cash and cash equivalents decreased to 65.73 million yuan from 135.22 million yuan at the beginning of the period[20] - Cash received from disposal of subsidiaries and other business units increased to 16.35 million yuan from 361,774.75 yuan[20] - Cash paid for construction of fixed assets and intangible assets decreased to 27.73 million yuan from 41.07 million yuan[20] - Cash received from borrowing decreased to 12.80 million yuan from 42.95 million yuan[20] - Cash paid for debt repayment decreased to 19.49 million yuan from 84.17 million yuan[20] - Cash paid for dividends, profits, and interest decreased to 55.38 million yuan from 128.26 million yuan[20] Expenses and Income - Government subsidies increased by 96.25% to RMB 1.74 million[7] - Investment income surged by 3221.14% due to the disposal of equity investments[7] - Asset disposal losses increased by 21433.38% due to asset disposals[7] - R&D expenses increased to 53,060,653.17 RMB from 44,798,579.22 RMB[16] - Sales expenses decreased to 209,877,172.55 RMB from 244,646,494.82 RMB[16] - Financial expenses decreased to 180,759,212.88 RMB from 184,314,075.37 RMB[16] - Asset impairment loss decreased to -1,493,143.68 RMB from -47,105,449.45 RMB[17] Business Transactions - The company transferred 51% equity of Beijing Xiangxue Pharmaceutical Biotechnology Co., Ltd. to Beijing Liuguitang Enterprise Management Technology Co., Ltd. for RMB 238.68 million[11] - The company's subsidiary, Guangdong Xiangxue Precision Medical Technology Co., Ltd., had its TAEST16001 injection included in the breakthrough therapy list by the National Medical Products Administration[12]